| 发明名称 |
TREATMENT OF IL-17 MEDIATED DISEASE BY BLOCKING SEFIR-SEFIR INTERACTIONS |
| 摘要 |
A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. In particular, it has been determined that the αC helix region of the SEFIR domain of both IL-17R and Act1 plays an important role in the association of IL-17R and Act1. To facilitate cell permeation, the decoy peptide is preferably conjugated to a protein transduction domain. Examples of IL-17 mediated diseases include various human and animal inflammatory and autoimmune diseases such as asthma. |
| 申请公布号 |
US2015158912(A1) |
申请公布日期 |
2015.06.11 |
| 申请号 |
US201214354608 |
申请日期 |
2012.10.29 |
| 申请人 |
THE CLEVELAND CLINIC FOUNDATION |
发明人 |
Li Xiaoxia;Liu Caini;Deng Junpeng;Hamilton Thomas A.;Zepp Jarod |
| 分类号 |
C07K7/08;C07K14/00;C07K7/06 |
主分类号 |
C07K7/08 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating an interleukin-17 (IL-17) mediated disease in a subject, comprising administering to the subject a therapeutically effective amount of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. |
| 地址 |
Cleveland OH US |
